Results 101 to 110 of about 142,764 (336)

Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites [PDF]

, 1991
Wladimiro Jiménez, Jolanta Gutkowska, Pere Ginès, Vicente Arroyo, Francisca Rivera, Joan Rodés   +5 more
openalex   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang, Chunlan Deng, Xiaogang Guo, Hui Yan   +3 more
wiley   +1 more source

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

Recurrence After Atrial Fibrillation Ablation and Investigational Biomarkers of Cardiac Remodeling

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Recurrence after atrial fibrillation (AF) ablation remains common. We evaluated the association between recurrence and levels of biomarkers of cardiac remodeling, and their ability to improve recurrence prediction when added to a clinical ...
Majd A. El‐Harasis, Joseph A. Quintana, J. Roberto Martinez‐Parachini, Gregory G. Jackson, Bibin T. Varghese, Zachary T. Yoneda, Brittany S. Murphy, Diane M. Crawford, Kelsey Tomasek, Yan Ru Su, Quinn S. Wells, Dan M. Roden, Gregory F. Michaud, Pablo Saavedra, Juan Carlos Estrada, Travis D. Richardson, Arvindh N. Kanagasundram, Sharon T. Shen, Jay A. Montgomery, Christopher R. Ellis, George H. Crossley, Magdalena Eberl, Ludovic Gillet, Andre Ziegler, M. Benjamin Shoemaker   +24 more
doaj   +1 more source

The atrial natriuretic factor. [PDF]

Heart, 1986
In less than three years since the rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats was reported the factor responsible for the diuretic, natriuretic, and vasodilating activity of the atrial homogenates was isolated, its chemical structure elucidated, and its total synthesis achieved. Also the cDNA and
openaire   +2 more sources

ANTIDIURESIS DURING PEEP IS HOT MEDIATED BY AN INHIBITION OF ATRIAL NATRIURETIC FACTOR RELEASE [PDF]

, 1988
M D Fratacci, E CRECK, R. Froidevaux, C Bellec, P Dupuy, Joëlle Eurin, Didier Payen   +6 more
openalex   +1 more source

Medical treatment of ascites in cirrhosis [PDF]

, 1993
Medical treatment of cirrhotic ascites is essentially supportive, dictated by the patient's discomfort, impaired cardiovascular or respiratory function and potential for infection. Treatment of ‘simple’ ascites (moderate fluid accumulation, serum albumin
Alexander L. Gerbes, Bernardi, Bichet, Bosch, Broekhuysen, Caramelo, Conn, DiBona, Epstein, Faloon, Fogel, Fuller, Ganger, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Gerbes, Ginès, Gregory, Guarner, Henriksen, Hoermann, Jüngst, Karnad, Keppler, Laffi, Lenz, Levy, Moore, Perez-Ayuso, Petrillo, Pockros, Ring-Larsen, Schrier, Schölmerich, Shear, Sherlock   +41 more
core   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Discovering a new role for the atrial natriuretic peptide: A novel risk factor for cardiovascular diseases

Heart International, 2006
Atrial natriuretic peptide, a diuretic, natriuretic and vasorelaxant hormone, is also involved in the regulation of cardiovascular remodeling and it has been recently shown to be significantly associated with higher occurrence of cardiovascular diseases.
Massimo Volpe, Speranza Rubattu
doaj   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source